ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment.

Luteolin Nanoparticle Pathological microenvironment ROS-Responsive Ulcerative colitis

Journal

Materials today. Bio
ISSN: 2590-0064
Titre abrégé: Mater Today Bio
Pays: England
ID NLM: 101757228

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 24 01 2022
revised: 16 03 2022
accepted: 19 03 2022
entrez: 4 4 2022
pubmed: 5 4 2022
medline: 5 4 2022
Statut: epublish

Résumé

Oxidative stress, caused by excessive production of reactive oxygen species (ROS), plays a crucial role in the occurrence and development of ulcerative colitis (UC). We developed ROS-responsive nanoparticles (NPs) as an efficacious nanomedicine against UC with oral administration. The NPs were fabricated with a d-α-tocopherol polyethylene glycol succinate-b-poly(β-thioester) copolymer (TPGS-PBTE) for ROS cleavage via the colitis-targeted delivery of luteolin (LUT), a natural flavonoid with good anti-inflammation and radical-scavenging activity. Owing to the thioether bond in the polymer main chain, the TPGS-PBTE NPs exhibited an ROS-responsive size change and drug release, which benefited the ROS-scavenging and selective accumulation of LUT in the inflamed colon. In a dextran sulfate sodium-induced acute colitis murine model, LUT@TPGS-PBTE NPs alleviated body weight loss, colon length shortening, and damage to the colonic tissues due to the suppression of ROS and proinflammatory cytokines (e.g., IL-17A, IL-6, interferon-γ, tumor necrosis factor-α), as well as upregulation of glutathione and anti-inflammatory factors (e.g., IL-10, IL-4). More importantly, LUT@TPGS-PBTE NPs regulated the inflammatory microenvironment by modulating the T helper (Th)1/Th2 and Th17/regulatory T cell (Treg) balance (i.e., increased numbers of Tregs and Th2 cells and decreased numbers of Th1 and Th17 ​cells), thus resolving inflammation and accelerating the healing of the intestinal mucosa. Additionally, the LUT@TPGS-PBTE NPs formulation enabled the reduction of the effective dose of LUT and showed excellent biosafety in the mouse model, demonstrating its potential as a targeted UC therapeutic oral preparation.

Identifiants

pubmed: 35372817
doi: 10.1016/j.mtbio.2022.100246
pii: S2590-0064(22)00044-8
pmc: PMC8965165
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100246

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Inflamm Bowel Dis. 2015 Jun;21(6):1409-18
pubmed: 25793328
Chem Biol Interact. 2012 Mar 5;196(1-2):30-8
pubmed: 22342831
Inflamm Bowel Dis. 2018 Jun 8;24(7):1401-1415
pubmed: 29788186
Immunity. 2019 Oct 15;51(4):671-681.e5
pubmed: 31451397
Biomaterials. 2016 Oct;105:206-221
pubmed: 27525680
Int J Pharm. 2020 Aug 30;586:119617
pubmed: 32650111
J Immunol. 2019 Dec 15;203(12):3436-3446
pubmed: 31732527
Pharmacol Ther. 2001 May-Jun;90(2-3):157-77
pubmed: 11578656
Immunity. 2004 Oct;21(4):467-76
pubmed: 15485625
Biochem Biophys Res Commun. 2018 May 23;499(4):727-734
pubmed: 29524405
J Gastroenterol. 2018 Mar;53(3):305-353
pubmed: 29429045
Gastroenterology. 2014 May;146(5):1289-300.e1-19
pubmed: 24503126
Cell. 2019 Aug 22;178(5):1041-1056
pubmed: 31442399
Biochem Pharmacol. 2013 Mar 15;85(6):798-807
pubmed: 23261528
J Control Release. 2021 Mar 10;331:515-524
pubmed: 33616078
Physiol Rev. 2014 Apr;94(2):329-54
pubmed: 24692350
PLoS One. 2017 Oct 6;12(10):e0185999
pubmed: 28985227
Adv Sci (Weinh). 2019 Aug 01;6(18):1900610
pubmed: 31559126
Curr Med Sci. 2020 Apr;40(2):218-231
pubmed: 32337683
Clin Transl Gastroenterol. 2016 Jan 07;7:e135
pubmed: 26741065
Adv Sci (Weinh). 2016 Jun 08;4(1):1600124
pubmed: 28105390
Int Immunopharmacol. 2016 Nov;40:24-31
pubmed: 27569028
Nat Mater. 2010 Nov;9(11):923-8
pubmed: 20935658
J Immunol. 1986 Apr 1;136(7):2348-57
pubmed: 2419430
Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):605-20
pubmed: 24798211
J Interferon Cytokine Res. 2010 Jun;30(6):399-406
pubmed: 20187766
Inflamm Bowel Dis. 2010 Oct;16(10):1808-13
pubmed: 20222127
Food Chem Toxicol. 2020 Nov;145:111680
pubmed: 32783997
J Gastroenterol. 2016 Aug;51(8):768-78
pubmed: 27048502
J Crohns Colitis. 2018 Nov 28;12(12):1448-1458
pubmed: 30137280
Front Cell Dev Biol. 2021 Jun 04;9:642948
pubmed: 34150751
Nature. 2010 Apr 29;464(7293):1381-5
pubmed: 20383124
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Gut. 2003 Jan;52(1):65-70
pubmed: 12477762
J Exp Med. 2021 Nov 1;218(11):
pubmed: 34529751
Adv Sci (Weinh). 2021 Sep;8(18):e2101619
pubmed: 34292669
Eur J Pharmacol. 2018 Feb 5;820:53-64
pubmed: 29225189
Front Microbiol. 2021 Jan 05;11:606605
pubmed: 33469451
Inflamm Bowel Dis. 2012 Jan;18(1):180-6
pubmed: 21381156
Carbohydr Polym. 2021 Dec 1;273:118612
pubmed: 34561010
J Immunol Res. 2021 Jan 18;2021:8883962
pubmed: 33532509
N Engl J Med. 2002 Aug 8;347(6):417-29
pubmed: 12167685
Gut. 2008 Sep;57(9):1185-91
pubmed: 18515412
Drug Deliv. 2017 Nov;24(1):1831-1842
pubmed: 29182031
J Infect Dis. 2004 Aug 1;190(3):624-31
pubmed: 15243941
Int J Nanomedicine. 2016 Oct 12;11:5287-5310
pubmed: 27789943
Mini Rev Med Chem. 2009 Jan;9(1):31-59
pubmed: 19149659
Life Sci. 2021 Mar 15;269:119008
pubmed: 33434535
J Transl Med. 2021 Jun 3;19(1):241
pubmed: 34082767
Antioxidants (Basel). 2021 Dec 03;10(12):
pubmed: 34943041
Nano Lett. 2016 Sep 14;16(9):5401-8
pubmed: 27490088
Asian J Pharm Sci. 2018 Mar;13(2):101-112
pubmed: 32104383
Nat Protoc. 2017 Jul;12(7):1295-1309
pubmed: 28569761
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
J Pharm Sci. 2014 Feb;103(2):687-96
pubmed: 24375287
Biomaterials. 2013 Apr;34(11):2843-54
pubmed: 23347838
Biomed Pharmacother. 2019 Jan;109:2396-2408
pubmed: 30551499
Nat Rev Immunol. 2003 Jul;3(7):521-33
pubmed: 12876555
Theranostics. 2021 Sep 13;11(19):9503-9518
pubmed: 34646383
Biomed Pharmacother. 2021 Jan;133:110937
pubmed: 33217689
Redox Biol. 2021 May;41:101881
pubmed: 33601276
Mayo Clin Proc. 2019 Jan;94(1):155-165
pubmed: 30611442

Auteurs

Chen Tan (C)

Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Heng Fan (H)

Department of Integrated Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Jiahui Ding (J)

School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Chaoqun Han (C)

Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Yang Guan (Y)

Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.

Feng Zhu (F)

Department of Integrated Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Hui Wu (H)

Department of Integrated Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Yujin Liu (Y)

Department of Integrated Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Wei Zhang (W)

School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Xiaohua Hou (X)

Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Songwei Tan (S)

School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Qing Tang (Q)

Department of Integrated Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Classifications MeSH